<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05123209</url>
  </required_header>
  <id_info>
    <org_study_id>YMCART202101</org_study_id>
    <nct_id>NCT05123209</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors</brief_title>
  <official_title>Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients Wirh Advanced Liver Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Immunochina Medical Science &amp; Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a open-label, single center, cohort study to determine the efficacy and safety of&#xD;
      IM83 CAR-T cells in patients with advanced Liver Tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 24, 2021</start_date>
  <completion_date type="Anticipated">August 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 30, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events (AEs) and abnormal laboratory test results as assessed by CTCAE V5.0</measure>
    <time_frame>Up to 28 days after CAR-T cell infusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>At 28 days, 3 months and 6 months after CAR-T cell infusion</time_frame>
    <description>ORR, defined as the proportion of participants with a complete response or partial response, as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>Up to 24 weeks after CAR-T cell infusion</time_frame>
    <description>DOR, defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first) in Stage 1, as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 24 weeks after CAR-T cell infusion</time_frame>
    <description>PFS, defined as the time from CAR-T cell infusion to the first occurrence of disease progression or death from any cause (whichever occurs first) , as determined by the investigator according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to 24 weeks after CAR-T cell infusion</time_frame>
    <description>OS , defined as the time from CAR-T cell infusion to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of α fetoprotein (AFP) cells infusion</measure>
    <time_frame>At 28 days, 3 months and 6 months after CAR-T cell infusion</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Persistence of CAR-T cells (cell counts and cell percentage in peripheral blood)</measure>
    <time_frame>Up to 24 weeks after CAR-T cell infusion</time_frame>
    <description>The persistence over time of CAR T cells in the peripheral blood as determined by flow cytometry and qPCR.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Liver Cancer</condition>
  <arm_group>
    <arm_group_label>IM83 CAR-T cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>IM83 CAR-T cells +The second-line treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>IM83 CAR-T cells</intervention_name>
    <description>3×10^9 CAR-T cells</description>
    <arm_group_label>IM83 CAR-T cells</arm_group_label>
    <arm_group_label>IM83 CAR-T cells +The second-line treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>The second-line treatment of liver cancer</intervention_name>
    <description>approved by NMPA</description>
    <arm_group_label>IM83 CAR-T cells +The second-line treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥ 18 years old, male or female.&#xD;
&#xD;
          -  Patients with advanced hepatocellular carcinoma (HCC) diagnosed by histopathology or&#xD;
             cytology, Barcelona stage B-C.&#xD;
&#xD;
          -  Progression or intolerance after receiving standardized systematic treatment in the&#xD;
             past (at least first-line treatment fails, and PD-1 / PD-L1 drugs can be used).&#xD;
&#xD;
          -  Patients in car-t combined treatment group need to have not received the combined&#xD;
             drugs before.&#xD;
&#xD;
          -  At least one measurable target lesion according to RECIST1.1.&#xD;
&#xD;
          -  Tumor cells expressed GPC3 antigen.&#xD;
&#xD;
          -  Child Pugh score of liver function ≤ 7.&#xD;
&#xD;
          -  ECOG 0-1.&#xD;
&#xD;
          -  Estimated survival ≥ 12 weeks;&#xD;
&#xD;
          -  Laboratory inspection shall at least meet the following specified indicators:&#xD;
&#xD;
        ANC≥ 1.5 × 10 ^ 9 / L，platelet ≥ 75 × 10 ^ 9 / L ，Hemoglobin ≥ 90 g / L，Serum creatinine ≤&#xD;
        1.5 ULN，serum bilirubin ≤ 3 ULN，INR≤ 2，AST and ALT)≤ 5.0 ULN，Creatinine clearance rate ≥ 60&#xD;
        ml / min.&#xD;
&#xD;
          -  The left ventricular ejection fraction was &gt; 50%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The researcher has determined that the subject has autoimmune diseases that are not&#xD;
             suitable to participate in this study, such as systemic lupus erythematosus,&#xD;
             rheumatoid arthritis, ulcerative colitis.&#xD;
&#xD;
          -  History of epilepsy or other central nervous system diseases that may affect the test&#xD;
             in the judgment of the investigator.&#xD;
&#xD;
          -  The washout period of chemotherapy, molecular targeted therapy, immunotherapy, hepatic&#xD;
             artery chemoembolization, radiofrequency ablation, radiotherapy for non target lesions&#xD;
             or other anti-tumor drugs within 1 week before blood collection is less than 5 half&#xD;
             lives.&#xD;
&#xD;
          -  Systemic glucocorticoids (local use is allowed) or other immunosuppressants were used&#xD;
             within 3 days before apheresis.&#xD;
&#xD;
          -  Other incurable malignant tumors in the past 5 years or at the same time, except&#xD;
             cervical carcinoma in situ, skin basal cell carcinoma and breast ductal carcinoma in&#xD;
             situ.&#xD;
&#xD;
          -  The investigator assessed that the subject had poorly controlled pleural effusion,&#xD;
             ascites or pericardial effusion.&#xD;
&#xD;
          -  Hypertension with poor drug control (systolic blood pressure &gt; 160mmhg and / or&#xD;
             diastolic blood pressure &gt; 90mmHg) or cardiovascular and cerebrovascular diseases with&#xD;
             clinical significance (such as active) within 6 months before signing the informed&#xD;
             consent, such as cerebrovascular accident, myocardial infarction, unstable angina&#xD;
             pectoris, or severe arrhythmia, which cannot be controlled by drugs or has potential&#xD;
             impact on the study treatment.&#xD;
&#xD;
          -  Combined with other serious organic diseases or mental diseases.&#xD;
&#xD;
          -  Subjects with HBsAg or HBcAbpositive and peripheral blood HBV DNA titers of &gt;2000&#xD;
             IU/ml (HBsAg positive but HBV DNA titer &lt;2000 IU/ml of peripheral blood and eligible&#xD;
             for antiviral treatment according to chronic hepatitis B prevention guideline 2019&#xD;
             Edition). HCV antibody positive and HCV RNA in peripheral blood &gt; 500 IU / ml.&#xD;
             Syphilis antibody positive.&#xD;
&#xD;
          -  Male subjects who are pregnant or breastfeeding during the screening period, or who&#xD;
             plan pregnancy during treatment or within 1 year after the end of treatment, or whose&#xD;
             partner plans pregnancy within 1 year after the end of treatment.&#xD;
&#xD;
          -  There were active or uncontrollable infections requiring systemic treatment within 1&#xD;
             week before cell apheresis.&#xD;
&#xD;
          -  Other researchers believe that it is not suitable for inclusion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fei Wu, MD</last_name>
    <phone>+8615801390058</phone>
    <email>wufei@immunochina.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chinese PLA GENERAL HOSPITAL</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100039</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianming Xu, M.D.</last_name>
      <phone>+8613910866712</phone>
      <email>Jianmingxu2014@163.com</email>
    </contact>
    <investigator>
      <last_name>Jianming Xu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

